A BILL 
To strengthen the use of patient-experience data within the 
benefit-risk framework for approval of new drugs. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Better Empowerment 
4
Now to Enhance Framework and Improve Treatments Act 
5
of 2021’’ or the ‘‘BENEFIT Act of 2021’’. 
6
03:51 Aug 01, 2021
H4472
2 
•HR 4472 IH
SEC. 2. STRENGTHENING THE USE OF PATIENT-EXPERI-
1
ENCE DATA WITHIN BENEFIT-RISK FRAME-
2
WORK. 
3
Section 569C of the Federal Food, Drug, and Cos-
4
metic Act (21 U.S.C. 360bbb–8c) is amended— 
5
(1) in subsection (a)(1)— 
6
(A) in subparagraph (A), by striking ‘‘; 
7
and’’ and inserting a semicolon; 
8
(B) in subparagraph (B), by striking the 
9
period and inserting ‘‘; and’’; and 
10
(C) by adding at the end the following: 
11
‘‘(C) as part of the risk-benefit assessment 
12
framework in the new drug approval process de-
13
scribed in section 505(d), considering relevant 
14
patient-focused drug development data, such as 
15
data from patient preference studies (benefit- 
16
risk), patient reported outcome data, or patient 
17
experience data, developed by the sponsor of an 
18
application or another party.’’; and 
19
(2) in subsection (b)(1), by inserting ‘‘, includ-
20
ing a description of how such data and information 
21
were considered in the risk-benefit assessment de-
22
scribed in section 505(d)’’ before the period. 
23
Æ 
03:51 Aug 01, 2021
H4472
